A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

  • Breast Cancer
  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer
Trial Status:

Active, not recruiting

This trial runs in
  • Agioi Anargyroi
  • Athens
  • Thessaloniki
Trial Identifier:

NCT02595762 ML28801

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (MBC).

      Hoffmann-La Roche Sponsor
      NCT02595762 , ML28801 Trial Identifier
      Metastatic Breast Cancer, Locally Advanced Breast Cancer Condition
      Official Title

      A Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Diagnosis of HER2-positive unresectable LABC or MBC within 6 months prior to enrollment
      Exclusion Criteria
      • None specified

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now